Schrödinger, Inc.

Schrödinger, Inc.

SDGR
Schrödinger, Inc.US flagNASDAQ Global Select
14.94
USD
-0.86
- -
1.12BMarket Cap
Schrödinger, Inc.
SDGR
(NASDAQ Global Select)

Recent

price

14.94

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.38
1.37
1.44
1.8
1.95
2.54
3.02
2.86
3.48
3.46
Revenue per Share
-0.43
-0.59
-0.41
-0.41
-1.42
-2.1
0.57
-2.57
-1.41
-1.4
Basic EPS, GAAP
-0.47
-0.6
-0.47
0.24
-1.1
-1.79
-2.09
-2.27
0.17
-2.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.29
-1.66
-1.76
-2.15
-3.25
-5.32
-4.7
-7.22
-8.55
-9.34
Book Value per Share
-1.12
-1.48
-1.57
10.4
7.89
6.22
7.58
5.73
4.89
4.19
Tangible Book Value per Share
40
48
60
60
71
71
72
73
73
74
Basic Weighted Avg Shares
56
67
86
108
138
181
217
208
256
255
Sales/Revenue/Turnover
-34.15
-41.97
-45.26
-56.35
-80.8
-81.13
-81.9
-100.85
-65.23
-64.65
Operating Margin (%)
2
3
4
4
3
4
6
6
6
6
Depreciation Expense
-17
-28
-25
-24
-100
-149
41
-187
-103
-103
Net Income, GAAP
- -
- -
- -
- -
- -
- -
5.12
- -
- -
1.4
Effective Tax Rate (%)
-31.23
-42.66
-28.72
-22.63
-72.78
-82.44
18.79
-90.16
-40.36
-40.6
Profit Margin (%)
30
78
74
610
534
425
434
443
330
294
Working Capital
- -
- -
9
7
78
105
111
101
93
91
LT Debt
-45
-72
-93
624
557
448
549
421
364
314
Total Equity
- -
- -
- -
- -
- -
- -
-27.14
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
17
16
16
LT Borrowings
- -
- -
- -
LT Finance Leases
95
93
91
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
74
74
75
Market Capitalization
1,478
1,317
837

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
472
519
464
Cash, Cash Equivalents & STI
391
395
399
Accounts Receivable, Net
29
83
27
Inventories
- -
- -
- -
Total Current Liabilities
145
189
170
Payables & Accruals
46
60
50
ST Debt
17
16
16
Deferred Revenue
82
113
103

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-8.93%
-13.62%
Free Cash Flow
- -
-132.73%
-107.56%
Net Income, GAAP
- -
-74.53%
-44.81%
Sales/Revenue/Turnover
- -
19.52%
23.29%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
37
47
35
88
208
2025
60
55
54
87
256
2026
59
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.76
-0.74
-0.52
- -
-2.57
2025
-0.81
-0.59
-0.45
- -
-1.41
2026
-0.81
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Schrödinger, Inc. (SDGR) develops physics-based computational platforms that accelerate the discovery of novel molecules for drug development and materials applications. The company offers a comprehensive suite of software products and services, including its flagship Schrödinger Platform comprising physics-based simulation software such as LiveDesign for collaborative design, Desmond and FEP+ for molecular dynamics and free energy perturbation calculations; Maestro for molecular visualization and modeling; and the Materials Science Suite for property prediction and optimization; alongside cloud-based services like Schrödinger Cloud for scalable computations, consulting services for custom model development, and enterprise solutions integrating AI-driven predictions with proprietary datasets. Founded in 1990 and headquartered in New York, the company primarily serves the biopharmaceutical, biotechnology, and chemical industries, with customers spanning North America, Europe, and Asia-Pacific regions, including major players like Pfizer, Takeda, and Novartis. In recent developments within the last two years, Schrödinger expanded its offerings through strategic collaborations, such as enhanced partnerships with biotech firms for AI-hybrid drug discovery pipelines, and continued investment in machine learning integrations to its platform amid growing demand for computational efficiency in R&D.

Company News

APIChat
  • Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

  • A Look at Schrodinger Inc (SDGR) After 6.9% Gain -- GF Value $26.55 vs Price $14.15

  • Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • My Top 3 Biotech Stocks for May 2026

  • 7 Healthcare AI Stocks Under $50 With Huge Upside Potential

  • Schrödinger, Inc. (SDGR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

  • Schrödinger, Inc. (SDGR) Q1 2026 Earnings Call Transcript

  • Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates

  • Schrödinger Reports First Quarter 2026 Financial Results

  • Schrödinger to Participate in Upcoming Investor Conferences

  • Schrodinger Inc (SDGR) Shares Fall 4.1% -- What GF Score of 69 Tells Investors

  • Schrödinger to Announce First Quarter 2026 Financial Results on May 5

  • Ramy Farid Sells 43,000 Shares of Schrodinger (NASDAQ:SDGR) Stock

  • Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • Schrodinger, Inc. (NASDAQ:SDGR) Given Average Recommendation of “Hold” by Brokerages

  • Schrödinger, Inc. (SDGR) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

  • Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • Schrödinger, Inc. (SDGR) Presents at TD Cowen 46th Annual Health Care Conference Transcript

  • Citigroup Inc. Grows Stake in Schrodinger, Inc. $SDGR

  • Schrödinger, Inc. (SDGR) Q4 2025 Earnings Call Transcript